Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...
Investing on MSN22h
Neurocrine Biosciences stock falls on revenue miss
Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® ...
Neurocrine price target lowered to $147 from $157 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the ...
Neurocrine price target lowered to $148 from $154 at RBC Capital
RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $148 from $154 and keeps a Sector Perform rating on the shares. The ...
TipRanks on MSN12h
Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
Neurocrine Biosciences (($NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences’ earnings call ...
Investor's Business Daily on MSN16h
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.